USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/2432
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMotriuc, Veronica
dc.date.accessioned2019-06-24T19:49:15Z-
dc.date.available2019-06-24T19:49:15Z-
dc.date.issued2013
dc.identifier.citationMOTRIUC, Veronica. Osteoporoza secundară hepatică. In: Anale ştiinţifice ale IP USMF “Nicolae Testemiţanu”. Ed. a 9-a. Chişinau: СEP Medicina, 2013, vol. 1: Probleme medico-biologice şi farmaceutice, pp. 153-158.en_US
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/2432-
dc.description(Coordonator ştiinţific: Olga Tagadiuc, conf. univ., dr. hab.) Catedra Biochimie şi Biochimie clinică, USMF ,,Nicolae Testemiţanu”en_US
dc.description.abstractLiver diseases, especially, the chronic ones, directly or/and indirectly affect bone metabolism and composition. Osteopenia and osteoporosis, which are generically called hepatic osteodystrophy, may develop. The condition has a complex mechanism in occurrence and development involving disorders of bone cell function and calcium-phosphorus metabolism, hormonal status (gonadotropins, estrogens, androgens, parathyroid),local regulatory mechanisms(osteocalcin, osteoprotegerin/RANKL/RANK system), vitamin levels (D and K), etc. Fragility fractures significantly increase mortality. Therefore, an assessment of bone metabolism, risk factors of hepatic osteodystrophy and bone mineral density is recommended in patients with chronic liver disease. An early diagnosis of hepatic osteodystrophy is essential for the correction of modifiable risk factors that predispose to bone loss and prevention of fragility fractures. Maladiile hepatice, în special, cele cronice afectează direct sau/şi indirect metabolismul şi compoziţia ţesutului osos. Se dezvoltă osteopenia şi osteoporoza, care poartă denumirea de osteodistrofie hepatică. Condiţia are un mecanism complex de apariţie şi dezvoltare, care implică dereglări ale funcţiilor celulelor osoase, precum şi ale metabolismului fosfo-calcic, statutului hormonal (gonadotropinele, estrogenii, androgenii, paratiroidul), mecanismelor reglatoare locale (osteocalcina, sistemul osteoprotegerină/RANKL/RANK), nivelului vitaminelor (D şi K), etc. Fracturile de fragilitate cresc semnificativ mortalitatea. Prin urmare, o evaluare a metabolismului osos, a factorilor de risc ai osteodistrofiei hepatice şi evaluarea densităţii minerale osoase sunt recomandate pacienţilor cu boli hepatice cronice. Un diagnostic precoce al osteodistrofiei hepatice este esenţial pentru a corecta factorii de risc modificabili care predispun la pierderea masei osoase şi prevenirea fracturilor de fragilitate.en_US
dc.language.isoroen_US
dc.publisherCEP "Medicina"en_US
dc.subjecthepatic osteodystrophyen_US
dc.subject.meshLiver Diseases - complicationsen_US
dc.subject.meshBone Diseases, Metabolicen_US
dc.subject.meshOsteoporosis - etiologyen_US
dc.subject.meshBone Diseases - etiologyen_US
dc.titleOsteoporoza secundară hepaticăen_US
dc.title.alternativeSecondary liver osteodystrophyen_US
dc.typeArticleen_US
Appears in Collections:Biochimie

Files in This Item:
File Description SizeFormat 
OSTEOPOROZA_SECUNDARA_HEPATICA.pdf302.8 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback